Organisation paid for research Program year 2025 Source: CMS Open Payments

USA Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$633,464

29 payments

Through program year 2025, USA Clinical Trials is reported as receiving $633,464 in research payments, across 29 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $421,478 17
2024 Research $60,791 7
2023 Research $141,558 3
2022 Research $9,637 2

Breakdown

Who paid Research payments · program years 2022–2025
  1. Pfizer Inc. $407,428 19 payments
  2. Merck Sharp & Dohme Corporation $221,563 8 payments
  3. Coloplast Corp $4,000 1 payment
  4. Organon LLC $473 1 payment
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3 Randomized Openlabel Study of Pf06821497 Mevrometostat in Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel in Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Mevpro1 $403,285 14 payments
  2. A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC $194,523 6 payments
  3. A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC $17,541 1 payment
  4. A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na to BCG Treatment KEYNOTE-676 $9,500 1 payment
  5. Intibia $4,000 1 payment
  6. A Phase 3 Randomized Double Blind Placebo Controlled Study of Pf06821497 Mevrometostat With Enzalutamide in Metastatic Castration Resistant Prostate Cancer Mevpro2 $1,982 2 payments
  7. A Phase 3 Randomized Openlabel Study of Pf06821497 Mevrometostat in Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel in Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Mevpro1 $1,982 2 payments
  8. 3475-676 $473 1 payment
  9. A Phase 1 Openlabel Dose Escalation and Dose Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics and Antitumor Activity of Pf08052667 As A Single Agent and in Combination Therapy in Participants 18 Years of Age and Older With Bladder Cancer $180 1 payment
What the money was spent on Research payments · program years 2022–2025
  1. Patient care $473 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record